Abstract: A preventing or treating agent for glaucoma is provided. This drug has a strong action of reducing intraocular pressure such that the intraocular pressure can be reduced even from the normal intraocular pressure. More specifically, a prophylactic or therapeutic agent for glaucoma, a preventing or treating agent for ocular hypertension, and eye drops containing (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl homopiperazine or its salt and phosphoric acid or its salt are provided.

Abstract: A preventing or treating agent for glaucoma is provided. This drug has a strong action of reducing intraocular pressure such that the intraocular pressure can be reduced even from the normal intraocular pressure. More specifically, a prophylactic or therapeutic agent for glaucoma, a preventing or treating agent for ocular hypertension, and eye drops containing (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl homopiperazine or its salt and phosphoric acid or its salt are provided.

Abstract: The present invention provides an indomethacin-containing external liquid preparation which provides good feeling of use, which exhibits high percutaneous absorption of indomethacin, and which, particularly in a low-temperature environment, does not cause precipitation of crystals with time. The present invention is drawn to an external liquid preparation containing indomethacin, a lower alcohol, water, a sulfite, and polyethylene glycol having an average molecular weight of 3,000 to 15,000.

Abstract: Provided is to enhance the therapeutic effect of an iontophoretic preparation for treatment of breast cancer or mastitis. An iontophoretic preparation for treatment of breast cancer and/or mastitis containing, as an active ingredient, a nonsteroidal anti-inflammatory analgesic agent and/or an anticancer agent, wherein an electrolyte is topically administered through the nipple part into the mammary gland; subsequently, a donor is applied to the nipple part; and the active ingredient is topically administered through the nipple part into the mammary gland by application of current.

Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.

Abstract: A composition containing an extremely poorly water-soluble drug and obtained by treating, with a supercritical fluid or subcritical fluid of carbon dioxide, a mixture comprising a porous silica material and the extremely poorly water-soluble drug; and its production process. The porous silica material has an average pore diameter in a range of from 1 to 20 nm, pores having diameters within ±40% of the average pore size account for at least 60% of a total pore volume of the porous silica material, and in X-ray diffractometry, the porous silica material has at least one peak at a position of diffraction angle (2?) corresponding to a d value of at least 1 nm. The composition according to the present invention, which contains the extremely poorly water-soluble drug, is excellent in the dissolution of the extremely poorly water-soluble drug.

Abstract: A composition containing a very low water-soluble drug, which composition is produced by treating, with a supercritical or subcritical carbon dioxide fluid, a mixture containing a very low water-soluble drug and a porous material (exclusive of a porous silica material characterized in that the material has an average pore diameter of 1 to 20 nm, the total pore volume of the material that have a diameter falling within a range of ±40% of the average pore diameter account for 60% or more the volume of all the pores of the material, and, when subjected to X-ray diffractometry, the material exhibits one or more peaks at a diffraction angle (2?) corresponding to d of 1 nm or more); and a method for producing the composition. The very-low-water-soluble-drug-containing composition of the present invention ensures improved dissolution of the very low water-soluble drug.

Abstract: An object of the invention is to provide a hydrous external skin patch, which has adherence sufficient for adhering to an affected area for several times without using an auxiliary tape or the like and is excellent in utility so that the patch can be easily peeled off even if the paste adheres to itself before application to the affected area. The hydrous external skin patch is characterized in that a paste of the patch comprises 0.1 to 10 wt % of a drug, 0.1 to 20 wt % of an adhesive base, 0.001 to 3.0 wt % of a crosslinker, 15 to 60 wt % of water, 2 to 20 wt % of a tackifier resin, 0.4 to 10 wt % of a dissolving agent for the tackifier resin, 0.1 to 30 wt % of an oil absorbing inorganic powder, and 0.1 to 20 wt % of a dextrin fatty acid ester and has a thickness of 100 to 1,000 ?m.

Abstract: An external preparation containing the following components (A), (B), (C), and (D): (A) a non-steroidal analgesic/anti-inflammatory agent, (B) a terpene and/or an essential oil containing a terpene, (C) a higher alcohol, and (D) a polyoxyalkylene alkyl ether and/or a polyoxyalkylene alkenyl ether. The external preparation of the present invention has improved skin permeation, and can thus be effective at a low concentration, and also has excellent appearance.

Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.

Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.

Abstract: Provided is to enhance the therapeutic effect of an iontophoretic preparation for treatment of breast cancer or mastitis. An iontophoretic preparation for treatment of breast cancer and/or mastitis containing, as an active ingredient, a nonsteroidal anti-inflammatory analgesic agent and/or an anticancer agent, wherein an electrolyte is topically administered through the nipple part into the mammary gland; subsequently, a donor is applied to the nipple part; and the active ingredient is topically administered through the nipple part into the mammary gland by application of current.

Abstract: A preventing or treating agent for glaucoma is provided. This drug has a strong action of reducing intraocular pressure such that the intraocular pressure can be reduced even from the normal intraocular pressure. More specifically, a prophylactic or therapeutic agent for glaucoma, a preventing or treating agent for ocular hypertension, and eye drops containing (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl homopiperazine or its salt and phosphoric acid or its salt are provided.

Abstract: An object of the invention is to provide a hydrous external skin patch, which has adherence sufficient for adhering to an affected area for several times without using an auxiliary tape or the like and is excellent in utility so that the patch can be easily peeled off even if the paste adheres to itself before application to the affected area. The hydrous external skin patch is characterized in that a paste of the patch comprises 0.1 to 10 wt % of a drug, 0.1 to 20 wt % of an adhesive base, 0.001 to 3.0 wt % of a crosslinker, 15 to 60 wt % of water, 2 to 20 wt % of a tackifier resin, 0.4 to 10 wt % of a dissolving agent for the tackifier resin, 0.1 to 30 wt % of an oil absorbing inorganic powder, and 0.1 to 20 wt % of a dextrin fatty acid ester and has a thickness of 100 to 1,000 ?m.

Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.

Abstract: The present invention provides an indomethacin-containing external liquid preparation which provides good feeling of use, which exhibits high percutaneous absorption of indomethacin, and which, particularly in a low-temperature environment, does not cause precipitation of crystals with time. The present invention is drawn to an external liquid preparation containing indomethacin, a lower alcohol, water, a sulfite, and polyethylene glycol having an average molecular weight of 3,000 to 15,000.

Abstract: An external preparation comprising following ingredients (A) and (B): (A) a compound represented by the following general formula (1) wherein R1 represents an organic residue having a cyclic structure that may have a substituent; R2 represents a hydrogen atom or a lower alkyl group; and X represents an ethylene group or an ethenylene group or a salt thereof, and (B) a monoterpene. The external preparation of the present invention is excellent in percutaneous absorbability.

Abstract: A composition containing a very low water-soluble drug, which composition is produced by treating, with a supercritical or subcritical carbon dioxide fluid, a mixture containing a very low water-soluble drug and a porous material (exclusive of a porous silica material characterized in that the material has an average pore diameter of 1 to 20 nm, the total pore volume of the material that have a diameter falling within a range of ±40% of the average pore diameter account for 60% or more the volume of all the pores of the material, and, when subjected to X-ray diffractometry, the material exhibits one or more peaks at a diffraction angle (2?) corresponding to d of 1 nm or more); and a method for producing the composition. The very-low-water-soluble-drug-containing composition of the present invention ensures improved dissolution of the very low water-soluble drug.

Abstract: A composition containing an extremely poorly water-soluble drug and obtained by treating, with a supercritical fluid or subcritical fluid of carbon dioxide, a mixture comprising a porous silica material and the extremely poorly water-soluble drug; and its production process. The porous silica material has an average pore diameter in a range of from 1 to 20 nm, pores having diameters within ±40% of the average pore size account for at least 60% of a total pore volume of the porous silica material, and in X-ray diffractometry, the porous silica material has at least one peak at a position of diffraction angle (2?) corresponding to a d value of at least 1 nm. The composition according to the present invention, which contains the extremely poorly water-soluble drug, is excellent in the dissolution of the extremely poorly water-soluble drug.

Abstract: A preventing or treating agent for glaucoma is provided. This drug has a strong action of reducing intraocular pressure such that the intraocular pressure can be reduced even from the normal intraocular pressure. More specifically, a prophylactic or therapeutic agent for glaucoma, a preventing or treating agent for ocular hypertension, and eye drops containing (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl homopiperazine or its salt and phosphoric acid or its salt are provided.